A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis

Journal of Substance Abuse Treatment

Volumn 40, Issue 1, 2011, Pages 95-101

  Dawe, Sharon ^a   Geppert, Leanne ^a   Occhipinti, Stefano ^a   Kingswell, William ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b Logan Hospital   (Australia)

Author keywords

Amphetamine; Cannabis; Mania; Positive symptoms; Psychosis

Indexed keywords

AMPHETAMINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CANNABIS ADDICTION; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIMARY PSYCHOTIC DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SUBSTANCE ABUSE; SUBSTANCE INDUCED PSYCHOSIS; SYMPTOM; URINALYSIS;

AMPHETAMINE-RELATED DISORDERS; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSION; DISEASE PROGRESSION; FEMALE; HUMANS; INPATIENTS; MALE; MARIJUANA ABUSE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; TIME FACTORS;

EID: 78649763563     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.08.002     Document Type: Article

References (32)

1. Caton C., Drake R., Hasin D., Dominguez B., Shrout P., Samet S., et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry 2005, 62:137-145.
2. Caton C.L.M., Hasin D.S., Shrout P.E., Drake R.E., Dominguez B., First M.B., et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. British Journal of Psychiatry 2007, 190:105-111.
3. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 1982, 8:470-484.
4. Carey K.B., Carey M.P., Maisto S.A., Henson J.M. Temporal stability of the Timeline Followback interview for alcohol and drug use with psychiatric outpatients. Journal of Studies on Alcohol 2004, 65:774-781.
5. Dawe S., Davis P., Lapworth K., McKetin R. Mechanisms underlying aggressive and hostile behaviour in amphetamine users. Current Opinion in Psychiatry 2009, 22:269-273.
6. Degenhardt L., Roxburgh A., McKetin R. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Medical Journal of Australia 2007, 186:342-345.
7. Fals Stewart W., O'Farrell T.J., Freitas T.T., et al. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology 2000, 68:134-144.
8. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
9. Green B.O.B., Young R., Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 2005, 187:306-313.
10. Hafner H., Riecher-Rossler A., Hambrecht M., et al. IRAOS: An instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research 1992, 6:209-223.
11. Harris D., Batki S.L. Stimulant psychosis: Symptom profile and acute clinical course. American Journal of Addiction 2000, 9:28-37.
12. Hall W., Hando J., Darke S., Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 1996, 91:81-87.
13. Hasin D.S., Samet S., Nunes E., Meydan J., Matseoane K., Waxman R. Diagnosis of comorbid disorders in substance users: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-IV). American Journal of Psychiatry 2006, 163:689-696.
14. Hasin D.S., Trautman K.D., Miele G.M., Samet M., Smith M., et al. Psychiatric research interview for substance and mental disorders: Reliability for substance abusers. American J. Psychiatry 1996, 153:1195-1201.
15. Iwanami A., Sugiyama A., Kuroki N., et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. Acta Psychiatrica Scandinavica 1994, 89:428-432.
16. Johns A. Psychiatric effects of cannabis. British Journal of Psychiatry 2001, 178:116-122.
17. Johnstone E.C., Crow T.J., Johnson A.L., MacMillan J.F., et al. The Northwick Park Study of First Episodes of Schizophrenia: I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986, 148:115-120.
18. Koen L., Kinnear C.J., Corfield V.A., et al. Violence in male patients with schizophrenia: Risk markers in a South African population. Australian and New Zealand Journal of Psychiatry 2004, 38:254-259.
19. McGrath J. The surprisingly rich contours of schizophrenia epidemiology. Archives of General Psychiatry 2007, 64:14-16.
20. Moos R.H., Moos R.H. Family Environment Scale Manual 1994, Consulting Psychologists Press, Palo Alto, CA. 3rd ed.
21. Nunez L.A., Gurpegui M. Cannabis-induced psychosis: A cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavaca 2002, 105:173-178.
22. Rasbash J., Steele F., Browne W., Prosser B. A User's Guide to MLwiN. Version 2.0 2005, University of Bristol, UK. http://www.mlwin.com.
23. Rottanburg D., Robins A., Ben-Arie O., et al. Cannabis-associated psychosis with hypomanic features. Lancet 1982, 18:1364-1366.
24. Rosenthal R., Miner C. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorders. Schizophrenia Bulletin 1997, 23:187-193.
25. Singer J., Willett J. Applied longitudinal data analysis: Modelling change and event occurrence 2003, Oxford University Press, USA.
26. Sobell L.C., Sobell M.B. Timeline Follow-back: A technique for assessing self-reported alcohol consumption. Measuring alcohol consumption: Psychosocial and biological methods 1992, 41-72. Humana Press Inc., New Jersey. R. Litten, J. Allen (Eds.).
27. SPSS Inc SPSS for Windows version 12.01 2003, SPSS Inc.
28. Srisurapanont M., Ali R., Marsden J., Sunga A., Wada K., Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmacology 2003, 6:347-352.
29. Swanson J.W., Swartz M.S., Van Dorn R.A., et al. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 2006, 63:490-499.
30. Vandevenne M., Vandenbussche H., Verstraete A. Detection time of drugs of abuse in urine. Acta Clinica Belgica 2000, 55:323-333.
31. Ventura J., Nuechterlein K.H., Subotnik K.L., et al. Symptom dimensions in recent-onset schizophrenia and mania: A principal components analysis of the 24-item brief psychiatric rating scale. Psychiatry Research 2000, 97:129-135.
32. Vollenweider F.X., Maguire R.P., Leenders K.L., et al. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Research 1998, 83:149-162.